Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580914 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
A NA study of Paroxysmal Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT04580914 is a NA study of Paroxysmal Atrial Fibrillation that has completed, run by Boston Scientific Corporation. The registered enrollment target is 321 participants, below the 846-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04580914, a NA study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.
Conditions Studied
Interventions
- DEVICE Treatment with IntellaNav StablePoint Ablation Catheter
Study Locations (20)
Florida
- AdventHealth Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
Illinois
- Loyola University Medical Center - Maywood
- St. John's Hospital - Springfield
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Mercy Hospital Medical Center - West Des Moines
New York
- Northwell Health - Bay Shore
- Weill Cornell Medical University - New York
Ohio
- Bethesda North Hospital - Cincinnati
- Cleveland Clinic Foundation - Cleveland
Arkansas
- Arrhythmia Research Group - Jonesboro
Hawaii
- The Queen's Medical Center - Honolulu
Idaho
- St. Lukes Idaho Cardiology Associates - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2023-06-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04580914
The ClinicalTrials.gov registry entry for NCT04580914 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 846-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (62% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Treatment with IntellaNav StablePoint Ablation Catheter is the first listed.
NCT04580914 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Illinois, Iowa.
Frequently Asked Questions
What is clinical trial NCT04580914 about?
NCT04580914 is a clinical study titled "Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation". The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.
What is the current status of trial NCT04580914?
This trial is currently completed. It is a NA study. The enrollment target is 321 participants. The study started on 2021-04-12. Estimated completion is 2023-06-21.
What conditions does trial NCT04580914 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT04580914?
The interventions under investigation include: Treatment with IntellaNav StablePoint Ablation Catheter (DEVICE).
Who is sponsoring clinical trial NCT04580914?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04580914 being conducted?
This trial has 20 study locations across Arkansas, Florida, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
POLARx Post Approval Study (POLARx PAS)
RECRUITING · NA
-
Treatment of PAF With the Synaptic System
ACTIVE NOT RECRUITING · NA
-
Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF)
ACTIVE NOT RECRUITING · NA
-
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.